Skip to content

EV / EBITDA at other companies

Amgen logo
AmgenAMGN
15.9×-1.3×
Moderna logo
ModernaMRNA
50.1×+46.6×
Royalty Pharma logo
Royalty PharmaRPRX
13.9×+1.7×
ALN
Alnylam PharmaceuticalsALNY
52.6×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×
Incyte logo
IncyteINCY
-28.2×

Other financials

Income statement

See full
Revenue$2.5M-66.7%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$22.44B+175%
Enterprise value$21.13B+157%
P/S2,716.9×+2,436×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Calculated from Roivant Sciences’s reported figures.

Based on the most recent quarter.

The official record: Roivant Sciences’s 10-Q, filed November 12, 2024, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's EV / EBITDA?
Roivant Sciences (ROIV) reported EV / EBITDA of 1.8× in Q3 2024.
What does EV / EBITDA mean?
What the whole business (debt included) costs relative to its operating cash earnings.
How do you interpret EV / EBITDA?
Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
How does EV / EBITDA compare across companies?
Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.